BioSpace News Archive

In two clinical studies (PROMISE-1 in episodic migraine and PROMISE-2 in chronic migraine), VYEPTI met its primary endpoint: decrease in mean monthly migraine days (MMD) over months 1-3.

Zhongchao Inc. announced the pricing of its initial public offering of 3,000,000 Class A ordinary shares at a public offering price of $4.00 per share.

NeuBase Therapeutics, Inc. announced that it received a standard notification letter dated February 20, 2020 from The Nasdaq Stock Market LLC stating that, as a result of not having timely filed its Quarterly Report on Form 10-Q for the period ended December 31, 2019, NeuBase is not in compliance with Nasdaq Listing Rule 5250, which requires timely filing of periodic financial reports with the Securities and Exchange Commission.

Aeterna Zentaris Inc. announced the closing of its previously announced registered direct offering with several institutional investors in the United States for 3,478,261 common shares, at a purchase price of $1.29375 per share, priced at-the-market under Nasdaq rules.

Eli Lilly and Company will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Thursday, February 27, 2020.

As concern over potential transmission of the Coronavirus to healthcare workers treating afflicted patients continues to rise, industry expert Radiation Shield Technologies is issuing a call-to-action to ensure healthcare workers have access to the necessary personal-protection gear.

Aurinia Pharmaceuticals Inc. announced that Mr. Peter Greenleaf, President and Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2019 at 10:00 a.m. ET in New York, NY.

Eli Lilly and Company will participate in the Cowen and Company 40th Annual Health Care Conference on Tuesday, March 3, 2020.

Arena Pharmaceuticals, Inc. announced that on February 10, 2020 the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 132,100 shares of its common stock to 20 new employees.

Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced that its board of directors has amended its shareholder rights plan.